Nordic Nanovector (Norway)

Recent papers from Nordic Nanovector (Norway)

1. Comprehensive Analysis of 177Lu-lilotomab Satetraxetan in Lymphoma Cell Lines: Implications for Precision Radioimmunotherapy and Combination Schemes2024
2. NNV024, a novel humanized anti-CD37 antibody with enhanced ADCC and prolonged plasma half-life in human FcRn transgenic mice for treatment of NHL2023
3. IOA-244 is a Non–ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune ToleranceCancer Research Communications · 2023
4. FDG PET/CT and Dosimetric Studies of 177Lu-Lilotomab Satetraxetan in a First-in-Human Trial for Relapsed Indolent non-Hodgkin Lymphoma—Are We Hitting the Target?Molecular Imaging and Biology · 2022
5. Anti-CD37 radioimmunotherapy with 177Lu-NNV003 synergizes with the PARP inhibitor olaparib in treatment of non-Hodgkin’s lymphoma in vitroPLoS ONE · 2022
6. 89Zr-PET imaging to predict tumor uptake of 177Lu-NNV003 anti-CD37 radioimmunotherapy in mouse models of B cell lymphomaScientific Reports · 2022
7. Myelosuppression in patients treated with¹⁷⁷Lutetium-lilotomab satetraxetan can be predicted with absorbed dose to the red marrow as the only variableActa Oncologica · 2021
8. FDG PET/CT parameters and correlations with tumor-absorbed doses in a phase 1 trial of 177Lu-lilotomab satetraxetan for treatment of relapsed non-Hodgkin lymphomaEuropean Journal of Nuclear Medicine and Molecular Imaging · 2020
9. Phase 1/2a study of 177Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphomaBlood Advances · 2020
10. ¹⁷⁷Lu-Lilotomab Satetraxetan Has the Potential to Counteract Resistance to Rituximab in Non-Hodgkin LymphomaJournal of Nuclear Medicine · 2020
11. Targeted alpha therapy for chronic lymphocytic leukaemia and non-Hodgkin’s lymphoma with the anti-CD37 radioimmunoconjugate 212Pb-NNV003PLoS ONE · 2020
12. Targeting B-cell malignancies with the beta-emitting anti-CD37 radioimmunoconjugate 177Lu-NNV003European Journal of Nuclear Medicine and Molecular Imaging · 2019
13. Administration of Beta-Emitting Anti-CD37 Radioimmunoconjugate Lutetium (177Lu) Lilotomab Satetraxetan as Weekly Multiple Injections Increases Maximum Tolerated Activity in Nude Mice with Non- Hodgkin Lymphoma XenograftsJournal of Cancer Biology and Therapeutics · 2018
14. Combination of 177Lu‐lilotomab with rituximab significantly improves the therapeutic outcome in preclinical models of non‐Hodgkin's lymphomaEuropean Journal Of Haematology · 2018
15. Pre-dosing with lilotomab prior to therapy with 177Lu-lilotomab satetraxetan significantly increases the ratio of tumor to red marrow absorbed dose in non-Hodgkin lymphoma patientsEuropean Journal of Nuclear Medicine and Molecular Imaging · 2018
16. Biodistribution and Dosimetry Results from a Phase 1 Trial of Therapy with the Antibody–Radionuclide Conjugate¹⁷⁷Lu-Lilotomab SatetraxetanJournal of Nuclear Medicine · 2017
17. Preparation of 212 Pb-labeled monoclonal antibody using a novel 224 Ra-based generator solutionNuclear Medicine and Biology · 2017
18. Red Marrow–Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with ¹⁷⁷Lu-Lilotomab Satetraxetan, a Novel Anti-CD37 Antibody–Radionuclide ConjugateJournal of Nuclear Medicine · 2016
19. Tumor-Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with the Anti-CD37 Antibody Radionuclide Conjugate 177Lu-Lilotomab SatetraxetanJournal of Nuclear Medicine · 2016
20. Targeted Cancer Therapy with a Novel Anti-CD37 Beta-Particle Emitting Radioimmunoconjugate for Treatment of Non-Hodgkin LymphomaPLoS ONE · 2015